Argenx SE - Company Profile
Powered by
All the data and insights you need on Argenx SE in one report.
$295
- Save hours of research time and resources with
our up-to-date Argenx SE Strategy Report
- Understand Argenx SE position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Argenx SE patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
HRP20180787T1 | Grant | GARP-TGF-BETA ANTIBODIES | A61K2039/505; C07K16/22; C07K16/28; C07K2317/22; C07K2317/32; C07K2317/33; C07K2317/526; C07K2317/55; C07K2317/56; C07K2317/565; C07K2317/732; C07K2317/76; C07K2317/92; C07K2317/94; C12N15/63 | September 16, 2022 |
AU2019397614B2 | Grant | Antibodies to human complement factor C2b and methods of use | A61K2039/505; A61K39/3955; A61P37/06; C07K14/472; C07K16/18; C07K2317/24; C07K2317/34; C07K2317/41; C07K2317/52; C07K2317/56; C07K2317/76 | September 15, 2022 |
US11434298B2 | Grant | Antibodies to CD70 | A61K2039/505; C07K16/2875; C07K16/2878; C07K2317/22; C07K2317/24; C07K2317/34; C07K2317/41; C07K2317/55; C07K2317/56; C07K2317/565; C07K2317/73; C07K2317/732; C07K2317/734; C07K2317/76; C07K2317/77; C07K2317/92; C07K2317/94 | September 06, 2022 |
IL294594A | Application | Methods for treating pemphigus disorders | A61K2039/505; A61K31/573; A61K38/1709; A61K39/395; A61K47/6811; A61K9/0019; A61P17/00; A61P37/06; C07K16/18; C07K2317/526; C07K2317/528 | September 01, 2022 |
US20220275035A1 | Application | FCRN ANTAGONISTS AND METHODS OF USE | A61K38/00; A61K38/1709; A61K45/06; C07K14/4703; C07K2317/41; C07K2317/52; C07K2317/524; C07K2317/526; C07K2317/94 | September 01, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer